Evidence map›Paper›PMID 37993584›Full record

ArticleScientific reports2023

NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma.

Naixue Wang, Dantong Zhu, Yao Liu, Jingran Wu, Meiling Wang, Shanxiu Jin, Fangwei Fu, Baolei Li, Hongjuan Ji, Cheng Du and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. [NPLOC4 promotes proliferation, invasion, and migration of hepatocellular carcinoma cells via enhancing Wnt/Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Naixue Wang *Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110011, China.
Dantong Zhu *Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110011, China.
Yao Liu *Guizhou Medical University, Guiyang, 550025, China.
Jingran WuDalian Medical University, Dalian, 116085, China.
Meiling WangDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, 110011, China.
Shanxiu JinDalian Medical University, Dalian, 116085, China.
Fangwei FuShenyang Pharmaceutical University, Shenyang, 110016, China.
Baolei LiJinzhou Medical University, Jinzhou, 121001, China.
Hongjuan JiJinzhou Medical University, Jinzhou, 121001, China.
Cheng DuDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, 110011, China. dc1115010@sina.com.
Zhendong ZhengDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, 110011, China. gcp_zzd@sina.com.
General Hospital of Shenyang Military Region · CNDalian Medical University · CNJinzhou Medical University · CNGuiyang Medical University · CNShenyang Pharmaceutical University · CN

Funding

Shenyang Science and Technology Bureau 213463Shenyang Science and Technology Bureau 22-321-32-09
6 · The paper itself

Abstract

Few prognostic biomarkers exist for lung squamous cell carcinoma (LUSC), which has a poor five-year survival rate. Using bioinformatics, this study evaluated NPLOC4 as a prognostic marker for patients with lung squamous cell carcinoma. Shorter survival periods and tumor growth were linked to high NPLOC4 expression.Disulfiram (DSF) combined with copper (Cu) targets NPLOC4 to achieve antitumor effects in lung squamous cell carcinoma. Thus, we investigated the effects of DSF with Cu in LUSC. Gene-set enrichment analysis identified ubiquitin-mediated proteolysis as the NPLOC4-associated mechanism influencing LUSC prognosis. In SK-MES-1 cell lines, DSF + Cu increased K48-linked ubiquitinated protein expression and apoptosis. This study identified NPLOC4 as a prognostic biomarker and a potential therapeutic target for LUSC.

Indexed as

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsDisulfiramHumansLungNuclear ProteinsPrognosisDisulfiramNPLOC4 protein, humanNuclear Proteins

Identifiers

PMID37993584
PMCPMC10665339
OpenAlexW4388912328

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.